Focus: Senti Biosciences is a South San Francisco-based biotechnology company focused on gene circuits and cell & gene therapies across respiratory, infectious disease, and oncology indications. The company is in early clinical stage with a pipeline spanning therapeutic devices and small-molecule therapeutics.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Senti is a technology-first, pre-clinical biotech best suited for scientists seeking foundational IP development and platform validation over near-term career security.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Senti Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Senti Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Acute Myeloid Leukemia Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
Acute Myeloid Leukemia Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Barchart.com
10 Overseas Regenerative Medicine Companies Deliver Pitches for Their Planned Expansion into Japan at the JEAP Demo Day | 2026 - Events & News - Investing in Japan - Japan External Trade Organization - JETRO - jetro.go.jp
10 Overseas Regenerative Medicine Companies Deliver Pitches for Their Planned Expansion into Japan at the JEAP Demo Day | 2026 - Events & News - Investing in Japan - Japan External Trade Organization - JETRO jetro.go.jp
A Paradigm Shift in Treating Adult AML? - The ASCO Post
A Paradigm Shift in Treating Adult AML? The ASCO Post
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial - Clinical Trials Arena
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial Clinical Trials Arena
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo